Effective immunotherapy promotes the killing of cancer cells by cytotoxic T cells. This requires not only that cancer-specific T cells be generated, but also that these T cells physically contact cancer cells. The coexistence in some patients of cancer cells and T cells that recognize them indicates that tumors may exhibit the phenomenon of immune privilege, in which immunogenic tissue is protected from immune attack. Here, we review the evidence that stromal cells of the tumor microenvironment mediate this restriction by excluding T cells from the vicinity of cancer cells. Overcoming this T cell checkpoint may thus enable optimal immunotherapy
The immune system can prevent tumour development by engaging in a process termed cancer immunosurvei...
Interactions between the immune system and tumors have been among the highlights of present immunolo...
Evidence suggests that cancer immunotherapy will be a major part of the combination treatment plan f...
Despite continual hints from preclinical and clinical research of its relevance, cancer immunology e...
Effective immunotherapy, whether by checkpoint blockade or adoptive cell therapy, is limited in most...
Tumor-specifi c cytotoxic T cells unleashed by the blockade of immune checkpoints have to overcome a...
For decades it has been assumed that T cells reject tumors essentially by direct killing. However, s...
An intact immune system is essential to prevent the development and progression of neoplastic cells ...
The development of cancer immunotherapies has been guided by advances in our understanding of the dy...
Generating an anti-tumor immune response is a multi-step process that is executed by effector T cell...
The onset of cancer is unavoidably accompanied by suppression of antitumor immunity. This occurs thr...
In the last decades, a novel field has emerged in the cure of cancer, by boosting the ability of the...
Effective antitumor immune response depends on the interaction between several components of the im...
T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in resected tum...
Immunotherapy is reshaping cancer treatment paradigms; however, response rates to immune therapies a...
The immune system can prevent tumour development by engaging in a process termed cancer immunosurvei...
Interactions between the immune system and tumors have been among the highlights of present immunolo...
Evidence suggests that cancer immunotherapy will be a major part of the combination treatment plan f...
Despite continual hints from preclinical and clinical research of its relevance, cancer immunology e...
Effective immunotherapy, whether by checkpoint blockade or adoptive cell therapy, is limited in most...
Tumor-specifi c cytotoxic T cells unleashed by the blockade of immune checkpoints have to overcome a...
For decades it has been assumed that T cells reject tumors essentially by direct killing. However, s...
An intact immune system is essential to prevent the development and progression of neoplastic cells ...
The development of cancer immunotherapies has been guided by advances in our understanding of the dy...
Generating an anti-tumor immune response is a multi-step process that is executed by effector T cell...
The onset of cancer is unavoidably accompanied by suppression of antitumor immunity. This occurs thr...
In the last decades, a novel field has emerged in the cure of cancer, by boosting the ability of the...
Effective antitumor immune response depends on the interaction between several components of the im...
T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in resected tum...
Immunotherapy is reshaping cancer treatment paradigms; however, response rates to immune therapies a...
The immune system can prevent tumour development by engaging in a process termed cancer immunosurvei...
Interactions between the immune system and tumors have been among the highlights of present immunolo...
Evidence suggests that cancer immunotherapy will be a major part of the combination treatment plan f...